Exhibit 10.48

​

​

AMENDMENT TO MEMBERSHIP AGREEMENT

​

​

HI PRINCESS BULANADI

​

Please review the Amendment to your Membership Agreement below.

​

If you have any questions or concerns, please don't hesitate to reach out to us at [email protected]

​

Reference is hereby made to the WeWork Membership Agreement between 200 Berkeley Street Tenant LLC ("WeWork") and NeuroBo Pharmaceuticals, Inc. dated January 29, 2020, including the accompanying Membership Details Form and any other amendments thereto (the "Agreement"). The parties agree that the following terms shall be considered binding amendments to the Agreement (the "Amendment"). Capitalized terms not defined herein shall have the meaning ascribed to them in the Agreement.

​

PRIMARY MEMBER INFORMATION

​

NeuroBo Pharmaceuticals, Inc.

Primary member: Princess Bulanadi

[email protected]

​

​

​

AMENDED MEMBERSHIP DETAILS

​

WeWork 200 Berkeley

​

Current Office(s)

​

19-120 • 2 person office

​

Membership Fee:

$1,340.00/mo from April 1, 2022

​

Commitment term

Start date: April 1, 2022

End date: June 30, 2022

​

​

​

​

​

MEMBERSHIP FEE SUMMARY

​

​

​

​

ANNUAL ESCALATION

​

On each anniversary of the start date for the office, the Membership Fee will be subject to an automatic three and a half percent (3.5%) increase over the then current Membership Fee.

​

This amendment may alter the date upon which Member Company's annual increase of the Membership Fee occurs, but in no event shall it occur on a date earlier than the next anniversary of the Start Date of the Agreement.

​

​

​

In the event of any inconsistency between the Agreement and this Amendment, the terms of this Amendment shall prevail. The parties further agree that other than the terms modified by this Amendment, the Agreement remains otherwise unchanged, including the annual Membership Fee increases set forth in the Agreement.

By electronically signing this Amendment you represent that you have the proper authority to execute this Amendment on behalf of NeuroBo Pharmaceuticals, Inc. and incur the obligations described in this Amendment on behalf of NeuroBo Pharmaceuticals, Inc.

​

​

​

​